
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA ...
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in …